Breaking News Instant updates and real-time market news.

GD

General Dynamics

$154.71

-0.45 (-0.29%)

17:32
10/03/16
10/03
17:32
10/03/16
17:32

General Dynamics awarded $106.2M government contract modification

General Dynamics National Steel and Shipbuilding Co., San Diego, California, is being awarded a $106,175,548 modification on a not-to-exceed basis to previously awarded, undefinitized contract action for the procurement of additional long lead time material, engineering, and non-production support for the Expeditionary Mobile Base 5. Work is expected to be completed by March 2017. Fiscal 2016 shipbuilding and conversion funding in the amount of $82,503,411 will be obligated at time of award and will not expire at the end of the current fiscal year. This contract was not competitively procured in accordance with U.S. Code 2304(c)(1) - only one responsible source and no other supplies or services will satisfy agency requirements. The Naval Sea Systems Command, Washington District of Columbia, is the contracting activity.

GD General Dynamics
$154.71

-0.45 (-0.29%)

05/17/16
COWN
05/17/16
NO CHANGE
Target $165
COWN
Outperform
General Dynamics price target raised to $165 from $158 at Cowen
Cowen raised its price target on General Dynamics to $165 from $158 and said they remain bullish on the stock, which is their top defense pick. The firm sees trough profit levels at Gulfstream, along with strong product momentum, defense EBIT growth and above average financial flexibility. Cowen reiterated its Outperform rating on General Dynamics shares.
08/10/16
BERN
08/10/16
UPGRADE
BERN
Outperform
General Dynamics upgraded to Outperform from Market Perform at Bernstein
08/10/16
BERN
08/10/16
UPGRADE
BERN
Outperform
General Dynamics upgraded to Outperform, valuation attractive, says Bernstein
As previously reported, Bernstein upgraded General Dynamics to Outperform from Market Perform and raised its price target to $180 from $168. Analyst Douglas Harned said shares of General Dynamics are valued at a larger discount to other prime contractors than it has been in the last 14 years and overly discounts weakness in the large cabin business jet market. Harned expects the defense business to grow from here with an increasing defense budget that supports Marine Systems and Combat Systems and sees little downside to shares even in a worst case scenario for Gulfstream.
08/10/16
08/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Outperform from Neutral at Macquarie with analyst Tim Nollen saying he thinks Disney owning this technology gives it commanding position on future content viewership as Bam Tech is a premier OTT streaming technology, allowing Disney to connect directly with consumers. 2. Coach (COH) upgraded to Neutral from Underperform at BofA/Merrill with analyst Lorraine Hutchinson saying management guided margins to 18.5-19%, in line with her 18.5% estimate, reflecting a strategic reduction in the wholesale business, thinks more realistic EBIT targets indicates management has de-risked its outlook, and expects consensus estimates to move towards hers. 3. Philips (PHG) upgraded to Buy from Neutral at UBS with the firm citing management's targets for margin growth, improved momentum in two key divisions, and the company's position in businesses that are likely to benefit from the secular shift toward value based care. 4. Yelp (YELP) upgraded to Outperform from Market Perform at Raymond James, to Neutral from Underperform at BofA/Merrill, to Buy from Hold at Axiom, and to Buy from Neutral at Mizuho. 5. General Dynamics (GD) upgraded to Outperform from Market Perform at Bernstein with Douglas Harned saying shares of General Dynamics are valued at a larger discount to other prime contractors than it has been in the last 14 years and overly discounts weakness in the large cabin business jet market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

KTOS

Kratos Defense

$12.72

-0.28 (-2.15%)

07:08
09/26/17
09/26
07:08
09/26/17
07:08
Hot Stocks
Kratos Defense receives $9.7M in contract awards »

Kratos Defense announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVGN

Evogene

$4.54

0.23 (5.34%)

07:08
09/26/17
09/26
07:08
09/26/17
07:08
Hot Stocks
Evogene reports 'positive' results in 2nd year field trials in banana »

Evogene announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXON

Axovant Sciences

$24.25

-0.74 (-2.96%)

07:06
09/26/17
09/26
07:06
09/26/17
07:06
Hot Stocks
Axovant Phase 3 Alzheimer's study misses co-primary endpoints »

Axovant Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AST

Asterias

$3.25

0.05 (1.56%)

07:06
09/26/17
09/26
07:06
09/26/17
07:06
Hot Stocks
Asterias receives regulatory clearance to start AST-VAC2 clinical trial »

Asterias Biotherapeutics,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MDXG

MiMedx

$12.35

-0.28 (-2.22%)

07:06
09/26/17
09/26
07:06
09/26/17
07:06
Hot Stocks
MiMedx announces confidential lawsuit settlement with terminated employee »

MiMedx Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 13

    Nov

  • 14

    Nov

DRI

Darden

$83.14

0.26 (0.31%)

07:06
09/26/17
09/26
07:06
09/26/17
07:06
Hot Stocks
Darden reports Q1 Olive Garden same-restaurant sales up 1.9% »

Reports Q1 same…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AGN

Allergan

$211.61

6.96 (3.40%)

07:05
09/26/17
09/26
07:05
09/26/17
07:05
Recommendations
Allergan analyst commentary  »

Allergan weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZRE

Azure Power

$16.18

0.18 (1.13%)

07:05
09/26/17
09/26
07:05
09/26/17
07:05
Hot Stocks
Azure Power awarded 260 MW solar project in Gujarat »

Azure Power announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEES

H&E Equipment

$26.97

-0.2 (-0.74%)

07:04
09/26/17
09/26
07:04
09/26/17
07:04
Initiation
H&E Equipment initiated  »

H&E Equipment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOG

Northern Oil and Gas

$0.94

0.093 (10.98%)

07:04
09/26/17
09/26
07:04
09/26/17
07:04
Hot Stocks
Northern Oil and Gas announces settlement with former CEO »

Northern Oil and Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$83.14

0.26 (0.31%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Hot Stocks
Breaking Hot Stocks news story on Darden »

Darden reports Q1 Olive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BTX

BioTime

$2.72

-0.08 (-2.86%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Hot Stocks
BioTime announces 'positive' secondary, long-term data from Renevia trial »

BioTime announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MBRX

Moleculin Biotech

$2.41

-0.07 (-2.82%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Hot Stocks
Moleculin Biotech announces FDA approval of Annamycin IND »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNCA

Genocea

$5.33

0.04 (0.76%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Downgrade
Genocea rating change  »

Genocea downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

DRI

Darden

$83.14

0.26 (0.31%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Hot Stocks
Darden reports Q1 blended same-restaurant sales from legacy brands up 1.7% »

Q1 same-restaurant sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AKBA

Akebia

$17.90

0.33 (1.88%)

07:02
09/26/17
09/26
07:02
09/26/17
07:02
Hot Stocks
Breaking Hot Stocks news story on Akebia »

Akebia: Phase 2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AXON

Axovant Sciences

$24.25

-0.74 (-2.96%)

07:02
09/26/17
09/26
07:02
09/26/17
07:02
Hot Stocks
Breaking Hot Stocks news story on Axovant Sciences »

Axovant announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$83.14

0.26 (0.31%)

07:02
09/26/17
09/26
07:02
09/26/17
07:02
Earnings
Darden backs FY18 adjusted cont ops EPS view $4.38-$4.50, consensus $4.47 »

The company reaffirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AKBA

Akebia

$17.90

0.33 (1.88%)

07:02
09/26/17
09/26
07:02
09/26/17
07:02
Hot Stocks
Breaking Hot Stocks news story on Akebia »

Akebia: Phase 3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AKBA

Akebia

$17.90

0.33 (1.88%)

07:01
09/26/17
09/26
07:01
09/26/17
07:01
Hot Stocks
Akebia saya Phase 2 vadadustat study confirmed findings from previous studies »

Akebia Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

07:00
09/26/17
09/26
07:00
09/26/17
07:00
General news
FX Update: The dollar has been in rally mode »

FX Update: The dollar has…

DIS

Disney

$99.57

0.97 (0.98%)

06:59
09/26/17
09/26
06:59
09/26/17
06:59
Periodicals
Disney streams theme-park events in new prototype stores, Bloomberg says »

Walt Disney is opening…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

SPX

S&P 500

06:59
09/26/17
09/26
06:59
09/26/17
06:59
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LCI

Lannett

$17.10

-0.3 (-1.72%)

06:58
09/26/17
09/26
06:58
09/26/17
06:58
Hot Stocks
Lannett revceives approval for Dexmethylphenidate Hydrochloride Tablets »

Lannett announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$23.83

0.36 (1.53%)

06:58
09/26/17
09/26
06:58
09/26/17
06:58
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.